학술논문
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen
Document Type
Article
Author
Source
In Experimental Hematology July 2022 111:79-86
Subject
Language
ISSN
0301-472X